Oncolytics Biotech announces issuance of 23rd United States patent.
"Recent research conducted by the United States National Cancer Institute and Cornell University demonstrated that administering reovirus in combination with various chemotherapeutic agents potentiates, or enhances tumour-killing, thus preventing the cancer cells from developing drug resistance," said Dr. Matt Coffey, Chief Scientific Officer. "This patent complements the combination REOLYSIN and chemotherapy clinical program that we are pursuing in the U.K."
Oncolytics is focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.
Oncolytics Biotech, Inc.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Aug 1, 2007|
|Previous Article:||Iowa State, Monsanto to collaborate on soybean technologies.|
|Next Article:||Pressure BioSciences issued first patent in Canada.|